oonal/iStock via Getty Images Evofem Biosciences ( OTCQB:EVFM ) Tuesday said that it has secured a new patent which covers composition and methods for contraception with a composition that encompasses Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel. Evofem Biosciences ( OTCQB:EVFM ) shares rose +3.45% to $0.
01. Phexxi is the first and only FDA-approved hormone-free, locally-acting contraceptive gel, Evofem Biosciences ( OTCQB:EVFM ) said. "We are extremely pleased with the continued development of the Phexxi patent portfolio, marked by the issuance of our fifth U.
S. patent," said Saundra Pelletier, Chief Executive Officer of Evofem. Source: Press Release More on Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Financial information for Evofem Biosciences.
